Cargando…
RAS at the Golgi antagonizes malignant transformation through PTPRκ-mediated inhibition of ERK activation
RAS GTPases are frequently mutated in human cancer. H- and NRAS isoforms are distributed over both plasma-membrane and endomembranes, including the Golgi complex, but how this organizational context contributes to cellular transformation is unknown. Here we show that RAS at the Golgi is selectively...
Autores principales: | , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6125387/ https://www.ncbi.nlm.nih.gov/pubmed/30185827 http://dx.doi.org/10.1038/s41467-018-05941-8 |
_version_ | 1783353154769780736 |
---|---|
author | Casar, Berta Badrock, Andrew P. Jiménez, Iñaki Arozarena, Imanol Colón-Bolea, Paula Lorenzo-Martín, L. Francisco Barinaga-Rementería, Irene Barriuso, Jorge Cappitelli, Vincenzo Donoghue, Daniel J. Bustelo, Xosé R. Hurlstone, Adam Crespo, Piero |
author_facet | Casar, Berta Badrock, Andrew P. Jiménez, Iñaki Arozarena, Imanol Colón-Bolea, Paula Lorenzo-Martín, L. Francisco Barinaga-Rementería, Irene Barriuso, Jorge Cappitelli, Vincenzo Donoghue, Daniel J. Bustelo, Xosé R. Hurlstone, Adam Crespo, Piero |
author_sort | Casar, Berta |
collection | PubMed |
description | RAS GTPases are frequently mutated in human cancer. H- and NRAS isoforms are distributed over both plasma-membrane and endomembranes, including the Golgi complex, but how this organizational context contributes to cellular transformation is unknown. Here we show that RAS at the Golgi is selectively activated by apoptogenic stimuli and antagonizes cell survival by suppressing ERK activity through the induction of PTPRκ, which targets CRAF for dephosphorylation. Consistently, in contrast to what occurs at the plasma-membrane, RAS at the Golgi cannot induce melanoma in zebrafish. Inactivation of PTPRκ, which occurs frequently in human melanoma, often coincident with TP53 inactivation, accelerates RAS-ERK pathway-driven melanomagenesis in zebrafish. Likewise, tp53 disruption in zebrafish facilitates oncogenesis driven by RAS from the Golgi complex. Thus, RAS oncogenic potential is strictly dependent on its sublocalization, with Golgi complex-located RAS antagonizing tumor development. |
format | Online Article Text |
id | pubmed-6125387 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | Nature Publishing Group UK |
record_format | MEDLINE/PubMed |
spelling | pubmed-61253872018-09-07 RAS at the Golgi antagonizes malignant transformation through PTPRκ-mediated inhibition of ERK activation Casar, Berta Badrock, Andrew P. Jiménez, Iñaki Arozarena, Imanol Colón-Bolea, Paula Lorenzo-Martín, L. Francisco Barinaga-Rementería, Irene Barriuso, Jorge Cappitelli, Vincenzo Donoghue, Daniel J. Bustelo, Xosé R. Hurlstone, Adam Crespo, Piero Nat Commun Article RAS GTPases are frequently mutated in human cancer. H- and NRAS isoforms are distributed over both plasma-membrane and endomembranes, including the Golgi complex, but how this organizational context contributes to cellular transformation is unknown. Here we show that RAS at the Golgi is selectively activated by apoptogenic stimuli and antagonizes cell survival by suppressing ERK activity through the induction of PTPRκ, which targets CRAF for dephosphorylation. Consistently, in contrast to what occurs at the plasma-membrane, RAS at the Golgi cannot induce melanoma in zebrafish. Inactivation of PTPRκ, which occurs frequently in human melanoma, often coincident with TP53 inactivation, accelerates RAS-ERK pathway-driven melanomagenesis in zebrafish. Likewise, tp53 disruption in zebrafish facilitates oncogenesis driven by RAS from the Golgi complex. Thus, RAS oncogenic potential is strictly dependent on its sublocalization, with Golgi complex-located RAS antagonizing tumor development. Nature Publishing Group UK 2018-09-05 /pmc/articles/PMC6125387/ /pubmed/30185827 http://dx.doi.org/10.1038/s41467-018-05941-8 Text en © The Author(s) 2018 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/. |
spellingShingle | Article Casar, Berta Badrock, Andrew P. Jiménez, Iñaki Arozarena, Imanol Colón-Bolea, Paula Lorenzo-Martín, L. Francisco Barinaga-Rementería, Irene Barriuso, Jorge Cappitelli, Vincenzo Donoghue, Daniel J. Bustelo, Xosé R. Hurlstone, Adam Crespo, Piero RAS at the Golgi antagonizes malignant transformation through PTPRκ-mediated inhibition of ERK activation |
title | RAS at the Golgi antagonizes malignant transformation through PTPRκ-mediated inhibition of ERK activation |
title_full | RAS at the Golgi antagonizes malignant transformation through PTPRκ-mediated inhibition of ERK activation |
title_fullStr | RAS at the Golgi antagonizes malignant transformation through PTPRκ-mediated inhibition of ERK activation |
title_full_unstemmed | RAS at the Golgi antagonizes malignant transformation through PTPRκ-mediated inhibition of ERK activation |
title_short | RAS at the Golgi antagonizes malignant transformation through PTPRκ-mediated inhibition of ERK activation |
title_sort | ras at the golgi antagonizes malignant transformation through ptprκ-mediated inhibition of erk activation |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6125387/ https://www.ncbi.nlm.nih.gov/pubmed/30185827 http://dx.doi.org/10.1038/s41467-018-05941-8 |
work_keys_str_mv | AT casarberta rasatthegolgiantagonizesmalignanttransformationthroughptprkmediatedinhibitionoferkactivation AT badrockandrewp rasatthegolgiantagonizesmalignanttransformationthroughptprkmediatedinhibitionoferkactivation AT jimenezinaki rasatthegolgiantagonizesmalignanttransformationthroughptprkmediatedinhibitionoferkactivation AT arozarenaimanol rasatthegolgiantagonizesmalignanttransformationthroughptprkmediatedinhibitionoferkactivation AT colonboleapaula rasatthegolgiantagonizesmalignanttransformationthroughptprkmediatedinhibitionoferkactivation AT lorenzomartinlfrancisco rasatthegolgiantagonizesmalignanttransformationthroughptprkmediatedinhibitionoferkactivation AT barinagarementeriairene rasatthegolgiantagonizesmalignanttransformationthroughptprkmediatedinhibitionoferkactivation AT barriusojorge rasatthegolgiantagonizesmalignanttransformationthroughptprkmediatedinhibitionoferkactivation AT cappitellivincenzo rasatthegolgiantagonizesmalignanttransformationthroughptprkmediatedinhibitionoferkactivation AT donoghuedanielj rasatthegolgiantagonizesmalignanttransformationthroughptprkmediatedinhibitionoferkactivation AT busteloxoser rasatthegolgiantagonizesmalignanttransformationthroughptprkmediatedinhibitionoferkactivation AT hurlstoneadam rasatthegolgiantagonizesmalignanttransformationthroughptprkmediatedinhibitionoferkactivation AT crespopiero rasatthegolgiantagonizesmalignanttransformationthroughptprkmediatedinhibitionoferkactivation |